Ribo Announces siRNA-based Treatment of Autoimmune Diseases (RBD2080) Received Clinical Approval in Australia

Ribo Announces siRNA-based Treatment of Autoimmune Diseases (RBD2080) Received Clinical Approval in Australia

First Milestone Successfully Achieved in Ribo’s Collaboration in Liver Diseases With Boehringer Ingelheim

First Milestone Successfully Achieved in Ribo’s Collaboration in Liver Diseases With Boehringer Ingelheim

Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics

Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase Ⅰ Clinical Data At ESC Congress 2024

Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase Ⅰ Clinical Data At ESC Congress 2024

Innovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNA

Innovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNA.